Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Federation of Pharmaceutical Industries"


4 mentions found


"Any changes to our incentives system would equally affect EU-based and foreign-based companies which bring medicines to the EU and, therefore, it would not put EU firms at a disadvantage," an EU Commission spokesperson said. Medication was the single biggest contributor to the EU’s trade surplus, with 235 billion euro ($252.13 billion) worth of exports in 2021. The EFPIA said small biotech companies have already moved to the United States and China. The Commission said its proposal would reduce new medicine approval times to 180 days from 400 days. Germany, Belgium and France would be the hardest hit by the proposed rules, the EFPIA said citing research by Dolon that it commissioned.
Persons: EFPIA, Lars Fruergaard Jorgensen, Jorgensen, Ozempic, " Jorgensen, Julia Payne, Lisa Shumaker Organizations: European Commission, European Federation of Pharmaceutical Industries, EU, Commission, Novo Nordisk, Thomson Locations: BRUSSELS, United States, China, Danish, Boston, U.S, Europe, EU, Germany, Belgium, France
European drug discounts will ruffle U.S. funder
  + stars: | 2023-04-28 | by ( ) www.reuters.com   time to read: +2 min
LODNON, April 28 (Reuters Breakingviews) - Europe’s plan to slash prices on pharmaceutical drugs could set off tensions with the U.S. The European Union proposed on Wednesday a legislative overhaul of the sector across the 27-nation bloc. This would incentivise drug makers like AstraZeneca (AZN.L) and GSK (GSK.L) to sell to all European countries at once. And although the U.S. is trying to tackle soaring prices with the Inflation Reduction Act, Europe’s falling drug costs will widen the gap once again. This creates a problem for the U.S. government, which funds more drug development than any other country.
A molecular biologist examines wastewater samples for pathogens in the safety laboratory at the Max Delbrück Center for Molecular Medicine in Mitte. One of the EU's key aims is to deliver more timely and equitable patient access to medicines across the 27-nation bloc. The group also found 92% of "innovative medicines" were available in Germany, compared with 30% in smaller and Eastern European EU member states. Companies can extend it up to 10 years if they launch the drug in all 27 EU member states within two years. However, pharmaceutical firms and lobby groups say the move could hamper innovation and the overall availability of drugs.
Комментируя переговоры главы государства, депутат от ПДС Раду Мариан сказал, что вакцина от Johnson & Johnson «идеально подойдет для РМ». Использование вакцины Johnson & Johnson приостановлено и в Европейских государствах. 14 апреля также стало известно, что Европейская комиссия в 2022 году не будет продлевать контракты на поставку вакцин от коронавируса с компаниями AstraZeneca и Johnson & Johnson. Ее клиентами были Pfizer, AstraZeneca, Johnson & Johnson и так далее, и тому подобное», — говорит Хаузер. Нравится нам то, что говорит австрийский политик или нет, но истории с вакцинами AstraZeneca и Johnson & Johnson, побуждает нас быть очень осторожными в оценках и в действиях.
Persons: Janssen Pharmaceutica, Johnson, Janssen COVAX, Майя Санду, Раду Мариан, Мариан, Майе Санду, Энтони Фаучи, Такер Карлсон, Серен Брострем, Джеральд Хаузер, Эмер Кук, Хаузер, СЕРГЕЙ ТКАЧ “Междуречье Organizations: Pfizer, AstraZeneca, FDA, Johnson, Fox News, Federation of Pharmaceutical Industries, AstraZeneca “, EMA, AstraZeneca Johnson, СМИ, ПДС, РМ, Центры по контролю и профилактике заболеваний, Европейская комиссия, Европейское агентство по лекарственным средствам, Европейская федерация фармацевтические отрасли и ассоциаций ( ) Locations: , Молдова, РМ, США, Европейские, Румыния, Дания, ЕС, Евросоюз, Брюссель, Европа
Total: 4